Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response

Abstract

The conceptual evolution of non-alcoholic fatty liver disease (NAFLD) to what, since 2023, is called metabolic dysfunction-associated steatotic liver disease (MASLD) not only represents a change in the classification and definition of the disease but also reflects a broader understanding of this heterogeneous condition, which still with many aspects to refine. Although the definition of NAFLD can be interchanged to a high percentage with the new MASLD concept in different aspects, MASLD has been proposed as a relevant factor that influences the response to new immunotherapeutic treatments in the management of MASLD-related hepatocellular carcinoma (HCC), compared to HCC of other etiologies. This indicates that the etiology of HCC plays a relevant role in the prognosis, highlighting the urgency of evaluating treatment regimens for this subgroup of patients in upcoming clinical trials. A better understanding of the pathophysiology of MASLD generates strategies that not only aid in its management but also provide strategies to directly intervene in the carcinogenesis of HCC.

Keywords

Hepatocellular carcinoma / NAFLD / MASLD / HCC therapy / immunotherapy

References

[1] Hagström H,Hegmar H.Natural history and progression of metabolic dysfunction-associated steatotic liver disease.Lancet Gastroenterol Hepatol2024;9:944-56

[2] Younossi ZM,Ong J.Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States.Clin Gastroenterol Hepatol2021;19:580-9.e5

[3] Younossi ZM,Younossi Y,Alqahtani SA.The impact of NASH to liver transplantations with hepatocellular carcinoma in the United States.Clin Gastroenterol Hepatol2022;20:2915-7.e1

[4] Sanyal AJ, Van Natta ML, Clark J, et al; NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 2021;385:1559-69. PMCID:PMC8881985

[5] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[6] Younossi ZM,Paik JM,Van Dongen C.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023;77:1335-47 PMCID:PMC10026948

[7] Riazi K,Charette JH.The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2022;7:851-61

[8] Llovet JM,Heikenwalder M.Immunotherapies for hepatocellular carcinoma.Nat Rev Clin Oncol2022;19:151-72

[9] Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1.

[10] Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542-56.

[11] Hsu CL.From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research.Nat Metab2024;6:600-2 PMCID:PMC11262457

[12] Hagström H,Allen AM.The future of international classification of diseases coding in steatotic liver disease: an expert panel Delphi consensus statement.Hepatol Commun2024;8:e0386 PMCID:PMC10843430

[13] Kanwal F,Loomba R.Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American association for the study of liver diseases practice guidance on nonalcoholic fatty liver disease.Hepatology2024;79:1212-9

[14] Rinella ME,Siddiqui MS.AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.Hepatology2023;77:1797-835 PMCID:PMC10735173

[15] Allen AM,Diehl AM,Lazarus JV.Envisioning how to advance the MASH field.Nat Rev Gastroenterol Hepatol2024;21:726-38

[16] Loomba R.Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.Aliment Pharmacol Ther2024;59:150-6 PMCID:PMC10807722

[17] Canivet CM,Loomba R.New nomenclature for nonalcoholic fatty liver disease: understanding metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction- and alcohol-associated liver disease, and their implications in clinical practice.Semin Liver Dis2024;44:35-42

[18] Pan Z,Al-Busafi SA.The MAFLD definition identifies three homogenous groups of patients.Liver Int2024;Online ahead of print:

[19] Pan Z,Abdulla M,Sebastiani G.MAFLD identifies patients with significant hepatic fibrosis better than MASLD.Hepatol Int2024;18:964-72

[20] Pan Z,AlNaamani K,Fan JG.MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease.Ann Hepatol2024;29:101512

[21] Pan Z,Esmat G,Eslam M.MAFLD predicts cardiovascular disease risk better than MASLD.Liver Int2024;44:1567-74

[22] Pennisi G,Celsa C.Clinical outcomes of MAFLD versus NAFLD: a meta-analysis of observational studies..Liver Int2024;44:2939-49

[23] Li M.Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?.J Hepatol2024;80:e53-4

[24] Díaz LA,Louvet A,Arrese M.The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol2023;20:764-83

[25] Arab JP,Trauner M.Recent insights into the pathogenesis of nonalcoholic fatty liver disease.Annu Rev Pathol2018;13:321-50

[26] Arab JP,Mathurin P.Alcohol-associated liver disease: integrated management with alcohol use disorder.Clin Gastroenterol Hepatol2023;21:2124-34

[27] Israelsen M,Johansen S,Krag A.MetALD: new opportunities to understand the role of alcohol in steatotic liver disease.Lancet Gastroenterol Hepatol2023;8:866-8

[28] Association for the Study of the Liver (EASL); Electronic address: [e-mail]; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO); European Association for the Study of the Liver (EASL). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).J Hepatol2024;81:492-542

[29] Petrie E,Bril F.Metabolic characteristics of patients with MetALD: caveats of a new definition.Liver Int2024;44:2929-38

[30] Ciardullo S,Morieri ML,Invernizzi P.Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence.Liver Int2024;44:1762-7

[31] Pennisi G,Romero-Gomez M.Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: a comparative analysis of various risk stratification criteria.Hepatology2024;79:912-25

[32] Talamantes S,Gilglioni EH,Ramos-Molina B.Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma.JHEP Rep2023;5:100811 PMCID:PMC10413159

[33] Simon TG,Chong DQ.Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies.Hepatology2018;67:1797-806 PMCID:PMC5906170

[34] Alexander M,van der Lei J.Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.BMC Med2019;17:95 PMCID:PMC6526616

[35] Kanwal F,Li L.Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease.Hepatology2020;71:808-19

[36] Habib S.Metabolic dysfunction-associated steatotic liver disease heterogeneity: need of subtyping.World J Gastrointest Pathophysiol2024;15:92791 PMCID:PMC11151879

[37] García-Nieto E,Rivas-Rivas C.Clinical and molecular characterization of steatotic liver disease in the setting of immune-mediated inflammatory diseases.JHEP Rep2024;6:101167 PMCID:PMC11474426

[38] Kanwal F,Mapakshi S.Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.Gastroenterology2018;155:1828-37.e2 PMCID:PMC6279617

[39] Byrne CD.MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome?.Metab Target Organ Damage2024;4:10

[40] Schwärzler J,Grander C,Tilg H.The pathophysiology of MASLD: an immunometabolic perspective.Expert Rev Clin Immunol2024;20:375-86

[41] Breasted JH. The edwin smith surgical papyrus. Available from: https://isac.uchicago.edu/sites/default/files/uploads/shared/docs/oip4.pdf. [Last accessed on 11 Nov 2024]

[42] Ebbell B. The Papyrus Ebers: the greatest Egyptian medical document. Levin & Munksgaard;1937. Available from: https://search.worldcat.org/zh-cn/title/The-Papyrus-Ebers-:-the-greatest-Egyptian-medical-document/oclc/5435947. [Last accessed on 11 Nov 2024].

[43] Hanahan D.Hallmarks of cancer: the next generation.Cell2011;144:646-74

[44] Hanahan D.The hallmarks of cancer.Cell2000;100:57-70

[45] Senga SS.Hallmarks of cancer-the new testament.Open Biol2021;11:200358 PMCID:PMC7881179

[46] Feinberg AP,Henikoff S.The epigenetic progenitor origin of human cancer.Nat Rev Genet2006;7:21-33

[47] Chen DS.Oncology meets immunology: the cancer-immunity cycle.Immunity2013;39:1-10

[48] Llovet JM,Singal AG.Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.Nat Rev Gastroenterol Hepatol2023;20:487-503

[49] Molinari M,Samra PB.Hepatic resection for hepatocellular carcinoma in nonalcoholic fatty liver disease: a systematic review and meta-analysis of 7226 patients.Ann Surg Open2021;2:e065 PMCID:PMC10455059

[50] Chin KM,Cheong CK.Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a meta-analysis and review of current literature.HPB2021;23:1164-74

[51] Lin YP,Wang CC.Impact of MAFLD on HBV-related stage 0/a hepatocellular carcinoma after curative resection.J Pers Med2021;11:684 PMCID:PMC8398387

[52] Wong RJ,Bonham CA,Esquivel CO.Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United network for organ sharing data.Clin Transplant2014;28:713-21

[53] Haldar D, Kern B, Hodson J, et al; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. J Hepatol 2019;71:313-22. PMCID:PMC6656693

[54] Zamora-Olaya JM,Alañón-Martínez PE.Donor atheromatous disease is a risk factor for hepatic artery thrombosis after liver transplantation.Clin Transplant2024;38:e15405

[55] Holzner ML,Schwartz ME.Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma.HPB2022;24:470-7

[56] Lewin SM,Kelley RK,Yao FY.Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.Liver Transpl2017;23:1015-22

[57] Hernandez-Alejandro R,Drage M.A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma.World J Gastroenterol2012;18:4145-9 PMCID:PMC3422794

[58] Kern B,Fritz J.High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation.Eur J Gastroenterol Hepatol2019;31:205-10

[59] Sadler EM,Bhat M.Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma.Transplantation2018;102:640-7

[60] Young S,Rubin N.Transarterial chemoembolization of hepatocellular carcinoma: propensity score matching study comparing survival and complications in patients with nonalcoholic steatohepatitis versus other causes cirrhosis.Cardiovasc Intervent Radiol2020;43:65-75

[61] Schotten C,Manka P.NAFLD-associated comorbidities in advanced stage HCC do not alter the safety and efficacy of yttrium-90 radioembolization.Liver Cancer2019;8:491-504 PMCID:PMC6883476

[62] Brunson C,Schaub D.Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis.Abdom Radiol2024;49:2714-25 PMCID:PMC11300538

[63] Rimassa L,Sangro B.Combination immunotherapy for hepatocellular carcinoma.J Hepatol2023;79:506-15

[64] Gordan JD,Abou-Alfa GK.Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update.J Clin Oncol2024;42:1830-50

[65] Guzman G,Petrovic LM,Layden TJ.Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?.Arch Pathol Lab Med2008;132:1761-6

[66] Vilar-Gomez E,Wai-Sun Wong V.Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.Gastroenterology2018;155:443-57.e17

[67] Bhala N,van der Poorten D.The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.Hepatology2011;54:1208-16 PMCID:PMC3238674

[68] Ekstedt M,Nasr P.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology2015;61:1547-54

[69] Orci LA,Caballol B.Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.Clin Gastroenterol Hepatol2022;20:283-92.e10

[70] Ioannou GN.Epidemiology and risk-stratification of NAFLD-associated HCC.J Hepatol2021;75:1476-84

[71] Behari J,Wang R.Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.Hepatol Commun2023;7:e00183 PMCID:PMC10319365

[72] Singh S,Wang Z,Murad MH.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol2015;13:643-54.e1-9 PMCID:PMC4208976

[73] Roskilly A,Taylor EJ,Parker R.Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis.Liver Int2021;41:982-95

[74] Le P,Zhang L.Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies.Clin Gastroenterol Hepatol2023;21:1154-68 PMCID:PMC9898457

[75] Estes C,Loomba R,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology2018;67:123-33 PMCID:PMC5767767

[76] Younossi ZM,Blissett R.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.Hepatology2016;64:1577-86

[77] White DL,El-Serag HB.Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.Clin Gastroenterol Hepatol2012;10:1342-59.e2 PMCID:PMC3501546

[78] Pennisi G,Romero-Gomez M.Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.Aliment Pharmacol Ther2022;55:604-15

[79] Angulo P,Dam-Larsen S.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology2015;149:389-97.e10 PMCID:PMC4516664

[80] Sanyal AJ,Ratziu V.The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials.Hepatology2019;70:1913-27

[81] Vitellius C,Lequoy M.MASLD-related HCC: multicenter study comparing patients with and without cirrhosis.JHEP Rep2024;6:101160 PMCID:PMC11474187

[82] Mittal S,Sada YH.Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2016;14:124-31.e1 PMCID:PMC4690789

[83] Wong CR,Nguyen MH,Lim JK.Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.Aliment Pharmacol Ther2017;46:1061-9

[84] Stine JG,Zimmet A.Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.Aliment Pharmacol Ther2018;48:696-703 PMCID:PMC7495494

[85] Tan DJH,Lin SY.Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.Lancet Oncol2022;23:521-30 PMCID:PMC9718369

[86] Kodama T.Molecular genealogy of metabolic-associated hepatocellular carcinoma.Semin Liver Dis2024;44:147-58 PMCID:PMC11245329

[87] Oh S,Jung S.Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression.Clin Mol Hepatol2024;30:247-62 PMCID:PMC11016492

[88] Huang G,Powell EE,Clark PJ.Gene variants implicated in steatotic liver disease: opportunities for diagnostics and therapeutics.Biomedicines2023;11:2809 PMCID:PMC10604560

[89] Stender S.PNPLA3 genotype and risk of liver and all-cause mortality.Hepatology2020;71:777-9 PMCID:PMC7979358

[90] Lewis CM.Polygenic risk scores: from research tools to clinical instruments.Genome Med2020;12:44 PMCID:PMC7236300

[91] Yang J,Nahon P.PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.Int J Cancer2019;144:533-44

[92] Bianco C,Pelusi S.Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol2021;74:775-82 PMCID:PMC7987554

[93] Thomas CE,Kuipers AL.NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population.Hepatol Commun2022;6:2310-21 PMCID:PMC9426386

[94] Chalasani N,Loomba R.PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.Hepatology2024;80:1212-26

[95] Muthiah MD.Burden of disease due to nonalcoholic fatty liver disease.Gastroenterol Clin North Am2020;49:1-23

[96] Li J,Yeo YH.Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2019;4:389-98

[97] Ye Q,Yeo YH.Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2020;5:739-52

[98] Younossi Z,Marietti M.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol2018;15:11-20

[99] Unalp-Arida A.Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population.Hepatology2020;71:820-34

[100] Petta S,Bugianesi E.Impact of PNPLA3 I148M on clinical outcomes in patients with MASLD.Liver Int2024;Online ahead of print:

[101] Lavrado NC,Cardoso CRL.Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.Liver Int2024;44:1042-50

[102] Seko Y,Shima T.Differential effects of genetic polymorphism on comorbid disease in metabolic dysfunction-associated steatotic liver disease.Clin Gastroenterol Hepatol2024;22:1436-43.e4

[103] Seko Y,Shima T.Clinical utility of genetic variants in PNPLA3 and TM6SF2 to predict liver-related events in metabolic dysfunction-associated steatotic liver disease.Liver Int2024;Online ahead of print:

[104] Sripongpun P,Mannalithara A.The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care.Hepatology2023;77:256-67 PMCID:PMC9613815

[105] Sripongpun P,Udompap P.Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score.JHEP Rep2024;6:101127 PMCID:PMC11403267

[106] Kaplan DE,Schwantes-An TH.Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction-associated steatotic liver disease.Hepatol Commun2024;8:e0487 PMCID:PMC11227360

[107] Hsu CK,Lai CC.Refining metabolic syndrome trait definitions in MASLD: a call for greater precision in cardiovascular risk assessment.Liver Int2024;Online ahead of print:

[108] Burke L,Haghnejad V,Parker R.Hepatocellular carcinoma risk scores for non-viral liver disease: a systematic review and meta-analysis.JHEP Reports2024;Online ahead of print:

[109] Kalligeros M,Younossi ZM.Metabolic dysfunction-associated steatotic liver disease and its link to cancer.Metabolism2024;160:156004

[110] Thomas JA,Dalais C,Thrift AP.Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis.Eur J Cancer2022;173:250-62

[111] Day CP.Steatohepatitis: a tale of two “hits”?.Gastroenterology1998;114:842-5

[112] Kazankov K,Thomsen KL.The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Nat Rev Gastroenterol Hepatol2019;16:145-59

[113] Hendrikx T,Kiss MG.Soluble TREM2 levels reflect the recruitment and expansion of TREM2⁺ macrophages that localize to fibrotic areas and limit NASH.J Hepatol2022;77:1373-85

[114] Zucman-Rossi J,Nault JC.Genetic landscape and biomarkers of hepatocellular carcinoma.Gastroenterology2015;149:1226-39.e4

[115] Sia D,Martinez-Quetglas I.Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features.Gastroenterology2017;153:812-26

[116] Jaitin DA,Thaiss CA.Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner.Cell2019;178:686-98.e14 PMCID:PMC7068689

[117] Fredrickson G,Barrow F.TREM2 macrophages mediate the beneficial effects of bariatric surgery against MASH.Hepatology2024;Online ahead of print:

[118] Ding T,Wang F.High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection.Hum Pathol2009;40:381-9

[119] Kuang DM,Peng C.Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.J Exp Med2009;206:1327-37 PMCID:PMC2715058

[120] Wang Q,Yu W,He Q.The core role of macrophages in hepatocellular carcinoma: the definition of molecular subtypes and the prognostic risk system.Front Pharmacol2023;14:1228052 PMCID:PMC10491020

[121] Zhao S,Liu J.Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate.Nature2020;579:586-91 PMCID:PMC7416516

[122] Hu C,Wang X.Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC.Hepatology2023;77:48-64 PMCID:PMC9970019

[123] Qin S, Chen M, Cheng AL, et al; IMbrave050 investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023;402:1835-47.

[124] Lencioni R,Erinjeri J.EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.JCO2024;42:LBA432

[125] Llovet J,Ren Z.LBA3 transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): phase III LEAP-012 study.Annals of Oncology2024;35:S1229

[126] Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.

[127] Cheng AL,Chen Z.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009;10:25-34

[128] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[129] Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-905.

[130] Ren Z, Xu J, Bai Y, et al; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol 2021;22:977-90.

[131] Kelley RK,Cheng AL.Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol2022;23:995-1008

[132] Abou-Alfa GK,Kudo M.Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evid2022;1:EVIDoa2100070

[133] Qin S,Meyer T.Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial.JAMA Oncol2023;9:1651-9 PMCID:PMC10557031

[134] Qin S, Chan SL, Gu S, et al; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 2023;402:1133-46.

[135] Galle PR,Kudo M.Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from checkmate 9DW.JCO2024;42:LBA4008

[136] Pfister D,Pinyol R.NASH limits anti-tumour surveillance in immunotherapy-treated HCC.Nature2021;592:450-6 PMCID:PMC8046670

[137] Ma C,Eggert T.NAFLD causes selective CD4⁺ T lymphocyte loss and promotes hepatocarcinogenesis.Nature2016;531:253-7 PMCID:PMC4786464

[138] Heinrich B,Diggs LP.Steatohepatitis impairs T-cell-directed immunotherapies against liver tumors in mice.Gastroenterology2021;160:331-45.e6 PMCID:PMC7755834

[139] Dudek M,Donakonda S.Auto-aggressive CXCR6⁺ CD8 T cells cause liver immune pathology in NASH.Nature2021;592:444-9

[140] Dudek M.Immature neutrophils bring anti-PD-1 therapy in NASH-HCC to maturity.Gut2022;Online ahead of print:

[141] Leslie J,Jamieson T.CXCR2 inhibition enables NASH-HCC immunotherapy.Gut2022;71:2093-106 PMCID:PMC9484388

[142] Espinoza M,Lim M,Singal AG.Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150.Gastroenterology2023;165:286-8.e4

[143] Llovet JM.Atezolizumab plus bevacizumab in advanced HCC: efficacy in NASH-specific etiology.Gastroenterology2023;165:1308-10

[144] Dong T,Liu Y.Roles of immune dysregulation in MASLD.Biomed Pharmacother2024;170:116069

[145] Donne R.The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma.Hepatology2023;77:1773-96 PMCID:PMC9941399

[146] Zhou PY,Gan W.Single-cell and spatial architecture of primary liver cancer.Commun Biol2023;6:1181 PMCID:PMC10661180

[147] Yahoo N,Knolle P.Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.J Hepatol2023;79:538-51

[148] Wang X,Dong B.Molecular mechanisms in MASLD/MASH-related HCC.Hepatology2024;Online ahead of print: PMCID:PMC11323288

[149] Guilliams M,Haest B.Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches.Cell2022;185:379-96.e38 PMCID:PMC8809252

[150] Tan J,Liu T.TREM2⁺ macrophages suppress CD8⁺ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma.J Hepatol2023;79:126-40

[151] Meyer T,Lopes A.Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease.J Hepatol2023;79:e73-6

[152] Rivera-Esteban J,Higuera M.Phenotypes of metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma.Clin Gastroenterol Hepatol2024;22:1774-89.e8

[153] Tabrizian P,Ajmera V.Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study.J Hepatol2024;Online ahead of print: